Last Price$65.21.3%
Market Cap$8,236.6M
22.4%
Peers median - 14.7%
46.1%
Peers median - (0.9%)
413.9%
Peers median - 8.2%
33.1%
Peers median - 1.9%
Competing with HALO
Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name | Market Cap | Quality rating | Intrinsic value | 1Y Return | Revenue | Free Cash Flow | Revenue growth | FCF margin | Gross margin | ROIC | Total Debt to Equity |
$8,236.6M | 7.6 | $56.1 13.8% overvalued | 62.0% | $1,015.3M | $468.4M | 22.4% | 46.1% | 80.8% | 33.1% | 413.9% | |
$129.6B | 5.8 | $143.8 71.4% overvalued | 21.0% | $11.0B | ($790.3M) | 11.5% | (7.2%) | 86.1% | (15.0%) | 10.7% | |
$70.9B | 6.5 | $1,008.1 53.1% undervalued | (31.9%) | $14.2B | $3,597.2M | 8.3% | 25.3% | 84.5% | 25.7% | 5.7% | |
$43.6B | 6.3 | $138.0 77.6% overvalued | 55.0% | $3,154.8M | ($58.8M) | 157.1% | (1.9%) | 74.8% | 73.0% | 0.7% | |
$36.4B | 5.2 | $86.2 69.6% overvalued | 93.2% | $2,248.2M | ($42.6M) | 23.0% | (1.9%) | 85.6% | (7.2%) | 1,931.9% | |
$22.9B | 6.0 | $330.6 246.7% undervalued | 3.7% | €2,751.1M | (€229.8M) | (28.0%) | (8.4%) | 80.3% | (37.8%) | 1.3% | |
$15.1B | 5.5 | $63.2 87.6% undervalued | 14.1% | $2,263.9M | $2,769.0M | (3.8%) | 122.3% | 73.9% | 14.5% | 73.6% | |
$14.3B | 6.0 | $0.6 97.1% overvalued | 456.3% | $0.0 | ($142.1M) | N/A | N/A | N/A | (3,335.4%) | 1.9% | |
$14.0B | 7.8 | $519.5 66.0% undervalued | 32.1% | $2,877.4M | $1,080.6M | 23.6% | 37.6% | 89.2% | 65.4% | 4.7% | |
$13.6B | 6.8 | $48.9 31.3% overvalued | (15.3%) | $2,850.5M | $475.4M | 17.8% | 16.7% | 78.6% | 11.0% | 10.7% | |
$1,846.9M | 5.5 | $2,907.4 1,182.4% undervalued | 39.9% | $3,316.8M | ($1,041.0M) | 50.5% | (31.4%) | 83.7% | (43.2%) | 32.1% |
Compare HALO Valuation Multiples with Peers
LTM
NTM
1Y Forward
2Y Forward
EV/Revenue
General
Valuation Multiple
Financial metrics
Company name
EV/Revenue
Revenue growth
EBITDA margin
Net Income margin
Halozyme Therapeutics, Inc.HALO
9.0x
22.4%
64.3%
43.7%
Median Peer Set
4.2x
14.8%
0.0%
(2.4%)
Alnylam Pharmaceuticals, Inc.ALNY
15.6x
23.0%
(38.6%)
(12.4%)
argenx SEARGX
12.8x
198.6%
(60.5%)
(24.1%)
BeiGene, Ltd.BGNE
0.1x
73.7%
467.1%
(35.9%)
BioMarin Pharmaceutical Inc.BMRN
4.6x
18.0%
139.3%
15.0%
BioNTech SEBNTX
1.7x
(27.9%)
N/A
(24.2%)
Regeneron Pharmaceuticals, Inc.REGN
3.9x
8.3%
10.4%
31.1%
Royalty Pharma plcRPRX
9.2x
(3.8%)
(43.7%)
37.9%
Summit Therapeutics Inc.SMMT
N/A
N/A
(68.7%)
N/A
United Therapeutics CorporationUTHR
3.8x
23.6%
25.7%
41.5%
Vertex Pharmaceuticals IncorporatedVRTX
11.4x
11.7%
N/A
(4.9%)
Compare HALO Valuation Multiples Dynamics with Peers
Crunching data... Almost there!
FAQ
1. How does Halozyme Therapeutics, Inc. (HALO) revenue growth compare to peers and the industry?
Halozyme Therapeutics, Inc. (HALO) revenue growth is 22.4%, compared to the peers' median of 14.7%.
2. How does Halozyme Therapeutics, Inc. (HALO) Free Cash Flow (FCF) margin compare to peers and the industry?
Halozyme Therapeutics, Inc. (HALO) FCF margin is 46.1%, compared to the peers' median of (0.9%).
3. How does Halozyme Therapeutics, Inc. (HALO) Total Debt to Equity ratio compare to peers and the industry?
Halozyme Therapeutics, Inc. (HALO) Total Debt to Equity ratio is 413.9%, compared to the peers' median of 8.2%.
4. How does Halozyme Therapeutics, Inc. (HALO) ROIC (Return on Invested Capital) compare to peers and the industry?
Halozyme Therapeutics, Inc. (HALO) ROIC is 33.1%, compared to the peers' median of 1.9%.